Please Wait...

Rates of Longitudinal Change in Brain Volume in a Clinical Trial of the Anti-Amyloid Vaccine, ACC-001

Gerald Novak, MD1, H. Robert Brashear, MD 2, Luc Bracoud, MSc3, Enchi Liu, PhD4, Steve Einstein, MS1, Florent Roche, MSc3, Joel Schaerer, PhD3, Chahin Pachai, PhD3, Nzeera Ketter, MD2

1 Janssen R&D, Titusville, NJ; 2 Janssen R&D, South San Francisco, CA; 3 BioClinica, Lyon, FR; 4 Janssen R&D, LaJolla, CA


Brain atrophy and ventricular enlargement are well described phenomena in Alzheimer's disease (AD), reflecting the extent of neurofibrillary pathology and cumulative neuronal and synaptic loss. The rate of change in these volumes, as quantified on MRI, has been used as a biomarker of progression of AD in clinical trials.

ACC-001 (vanutide cridificar), a vaccine consisting of N-terminal peptides of Aβ42 combined with the adjuvant Quillaja saponaria (QS-21), induces antibodies that bind to the N-terminus of the Aβ peptide.

In a recently-completed phase 2 study, the effect of ACC-001 on rate of change of whole brain, ventricular, and hippocampal volume in subjects with mild to moderate AD was assessed with volumetric magnetic resonance imaging (vMRI).


Assessment of change from baseline in brain volume, an indicator of disease progression and potential effect of treatment, was an exploratory objective in this Phase 2 study.

The primary objective was the evaluation of effect of ACC-001+QS-21 compared to placebo on removing cerebral fibrillar amyloid in subjects with mild to moderate AD, as evidenced by florbetapir PET.

Other objectives included

Evaluation of the safety of ACC-001+QS-21 compared to placebo

Assessment of clinical efficacy

Assessment of effects on CSF Aβ, tau, and p-tau and on plasma Aβ

Assessment of Immunogenicity (serum IgG/IgM titer)


Study design:

Randomized, double-blind, placebo-controlled

Patients aged 50-89 year, with mild to moderate AD

Baseline mini-mental status examination scores 18-26

Positive florbetapir PET based on visual interpretation.

Randomized 1:1:1 to 3 µg or 10 µg of ACC-001/QS-21 or placebo, stratified by ApoE4 status.

Treatment given by intramuscular injections over 18 months at Weeks 0, 4, 12, 26, 52 and 78, with follow up through Week 104.

Endpoints included:

Changes from baseline in whole brain, ventricular, and right and left hippocampal volume (indexed by brain, ventricular and R and L hippocampal boundary shift integrals; BBSI, VBSI, and L and RHBSI, respectively), assessed at screening and Weeks 24, 50, 76 and 102

Change in florbetapir PET GCA SUVr at Week 104

Clinical efficacy - change from baseline to Week 104 in the following:

11-item Alzheimer's Disease Assessment Scale – cognition (ADAS-Cog/11)

Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB)

Disability Assessment in Dementia (DAD)

Mini-Mental Status Examination (MMSE)


All subjects underwent MRI examinations at screening and Weeks 2, 10, 24, 50, 76 and 102, composed of a high-resolution 3DT1 sequence in compliance with the ADNI-1 imaging protocol, FLAIR, T2, T2* and DWI.

All MRI data were sent for central processing and eligibility/safety monitoring to BioClinica; only datasets with good quality scans (no significant imaging artifacts, same MRI scanner used across timepoints) were considered for volumetric analysis.

The volumes of whole brain, lateral ventricles and hippocampus were assessed at screening using a fully-automated atlas-based segmentation algorithms (Figure 1), and volume changes at follow-up timepoints were assessed using BBSI, VBSI, LHiBSI, and RHiBSI.

Data analysis:

BSI measures were converted to a rate of change per year by taking the change in baseline volume (in mL), dividing by the number of days since the baseline scan, and multiplying by 365.25.

Treatment differences (ACC-001/QS21 minus placebo) were analyzed by a mixed model for repeated measures (MMRM) with annualized xBSI as the response variable; the fixed effect model terms included:

treatment (3 μg, 10 μg or placebo)

visit (scheduled week)

treatment-by-visit interaction

baseline whole brain volume

APOE*E4 status (carrier or noncarrier) baseline age.

Treatment effects were estimated using least-squares (LS) means with factor levels weighted according to overall baseline sample proportions.


Demographics were generally balanced across treatment groups, though slight differences in several baseline characteristics suggest that subjects randomized into the placebo arm had slightly less severe AD (Table 1).

At Week 102, the LS mean annualized BBSI (±SE) was significantly greater for the 10 µg ACC-001/QS21 group than for placebo (Table 2 and Figure 2). BBSI was intermediate for the 3 µg group, but not significantly different from placebo.

The difference relative to placebo was greatest in the subset of patients receiving 10 µg ACC-001/QS21 with moderate AD (MMSE < 20) than for mild AD (MMSE > 21) (Table 3 and Figure 3).

A similar pattern of volume change (10 µg > 3 µg > placebo) was seen for VBSI, LHBSI and RHBSI, but neither of the differences relative to placebo were statistically significant (Table 2 and Figures 2 and 4).

There were no statistically significant differences between either dosage and placebo for ADAS-Cog/11, CDR-SB, MMSE, or DAD.

A total of 5 subjects (2 receiving 3 µg ACC-001/QS21 and 3 receiving 10 µg ACC-001/QS21) developed amyloid-related imaging abnormalities (ARIA-E); all were asymptomatic and resolved.


Immunization with ACC-001, at a dosage of 10 µg in combination with QS21, was associated with a greater rate of whole brain atrophy, as indexed by BBSI, compared to placebo.

These results are consistent with other anti-amyloid immunotherapeutic agents, including the vaccine AN-1792 and the monoclonal antibody, bapineuzumab. The explanation for this incremental volume reduction is unknown; hypotheses have included clearance of amyloid plaques, reduction of inflammatory components and shifts of interstitial fluid from amyloid-laden perivascular pathways.




Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

A great resource for Alzheimers's research teams.
bioclinica (12 hours ago)
RT @bioclinica: #Pharmacovigilance: Get up-to-speed on latest ind. trends & best practices + hear how others R meeting today's most pressin…
bioclinica (13 hours ago)
RT @Xtalks: Trends in #Pharmacovigilance – Market Research and Future Impact This webinar will discuss an overview of key findings within r…
bioclinica (13 hours ago)
RT @IntClinTrials: Patient loss and can reduced by introducing new methods during the follow-up period. Martin Collyer at @bioclinica tells…
bioclinica (13 hours ago)
@bioclinica experts talk candidly about #Alzheimer's research & where improvements can be made. Joyce Suhy, Marieke…
bioclinica (13 hours ago)
RT @ACROhealth: @MaryWolleyRA Mary Woolley @ResearchAmerica: 80% have heard of #clinicaltrials. 75% think trial participation is as importa…
bioclinica (1 week ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen